Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.

TitleGlobal site-specific N-glycosylation analysis of HIV envelope glycoprotein.
Publication TypeJournal Article
Year of Publication2017
AuthorsCao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park S-KRobin, Sok D, Su CYao, Delahunty CM, Menis S, Andrabi R, Guenaga J, Georgeson E, Kubitz M, Adachi Y, Burton DR, Schief WR, Iii JRYates, Paulson JC
JournalNat Commun
Volume8
Pagination14954
Date Published03/28/2017
ISSN2041-1723
Abstract

HIV-1 envelope glycoprotein (Env) is the sole target for broadly neutralizing antibodies (bnAbs) and the focus for design of an antibody-based HIV vaccine. The Env trimer is covered by ∼90N-linked glycans, which shield the underlying protein from immune surveillance. bNAbs to HIV develop during infection, with many showing dependence on glycans for binding to Env. The ability to routinely assess the glycan type at each glycosylation site may facilitate design of improved vaccine candidates. Here we present a general mass spectrometry-based proteomics strategy that uses specific endoglycosidases to introduce mass signatures that distinguish peptide glycosites that are unoccupied or occupied by high-mannose/hybrid or complex-type glycans. The method yields >95% sequence coverage for Env, provides semi-quantitative analysis of the glycosylation status at each glycosite. We find that most glycosites in recombinant Env trimers are fully occupied by glycans, varying in the proportion of high-mannose/hybrid and complex-type glycans.

DOI10.1038/ncomms14954
Alternate JournalNat Commun
PubMed ID28348411
PubMed Central IDPMC5379070
Grant ListP41 GM103533 / GM / NIGMS NIH HHS / United States
R01 AI113867 / AI / NIAID NIH HHS / United States
UM1 AI100663 / AI / NIAID NIH HHS / United States
CHAVI-ID: 
1
Cover Picture: